American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they don't receive federal funding connected to the mRNA research cuts announced ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...